EUVIMEDEUVIMED entdecken
Open Access

Disease Severity Staging System for NOTCH3 -Associated Small Vessel Disease, Including CADASIL

Gido Gravesteijn, Julie W Rutten, Minne N Cerfontaine, Remco J Hack, Yi-Chu Liao, Amy A Jolly, Stéphanie Guey, Shao-Lun Hsu, Jae-Young Park, Yun Yuan, Anna Kopczak, Nicola Rifino und 38 weitere

JAMA Neurology · 01.01.2025 · 82 (1) · 49

DOI: 10.1001/jamaneurol.2024.4487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Neurology, erschienen am 01.01.2025. Verfasst von Gido Gravesteijn und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Receptor, Notch3, CADASIL, Severity of Illness Index, Cerebral Small Vessel Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Typical cysteine-altering NOTCH3 ( NOTCH3 cys ) variants are highly prevalent (approximately 1 in 300 individuals) and are associated with a broad spectrum of small vessel disease (SVD), ranging from early-onset stroke and dementia (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]) to nonpenetrance. A staging system that captures the full NOTCH3 -SVD severity spectrum is needed and currently lacking.

Objective

To design a simple disease severity staging system that captures the broad clinicoradiological NOTCH3 -SVD severity spectrum. Design, Setting, and Participants A cohort study was performed in which the NOTCH3 -SVD severity staging system was developed using a discovery cohort (2019-2020) and validated in independent international CADASIL cohorts (1999-2023) and the UK Biobank. Clinical and imaging data were collected from participants originating from 23 international CADASIL cohorts and from the UK Biobank. Eligibility criteria were presence of a NOTCH3 cys variant, availability of brain magnetic resonance imaging, and modified Rankin Scale score. The discovery cohort consisted of 195 NOTCH3 cys -positive cases from families with CADASIL; the validation set included 1713 NOTCH3 cys -positive cases from 15 countries. The UK Biobank cohort consisted of 101 NOTCH3 cys -positive individuals. Data from 2-year (2019-2023) and 18-year (1999-2017) follow-up studies were also analyzed. Data analysis was performed from July 2023 to August 2024. Main Outcomes and Measures Percentage of cases following the sequence of events of the NOTCH3 -SVD stages, and the association between the stages and ischemic stroke, intracerebral hemorrhage, global cognition, processing speed, brain volume, brain microstructural damage, and serum neurofilament light chain (NfL) level.

Results

The NOTCH3 -SVD staging system encompasses 9 disease stages or substages, ranging from stage 0 (premanifest stage) to stage 4B (end stage). Of all 1908 cases, which included 195 in the discovery cohort (mean [SD] age, 52.4 [12.2] years) and 1713 in the validation cohorts (mean [SD] age, 53.1 [13.0] years), 1789 (94%) followed the sequence of events defined by the NOTCH3 -SVD staging system. The NOTCH3 -SVD stages were associated with neuroimaging outcomes in the NOTCH3 cys -positive cases in the CADASIL cohorts and in the UK Biobank and with cognitive outcomes and serum NfL level in cases from the CADASIL cohorts. The NOTCH3 -SVD staging system captured disease progression and was associated with 18-year survival. Conclusions and Relevance The NOTCH3 -SVD staging system captures the full disease spectrum, from asymptomatic individuals with a NOTCH3 cys variant to patients with end-stage disease. The NOTCH3 -SVD staging system is a simple but effective tool for uniform disease staging in the clinic and in research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Notch3CADASILSeverity of Illness IndexCerebral Small Vessel DiseasesHumansFemaleMiddle AgedMaleCohort StudiesAdultMagnetic Resonance ImagingAged

Substanzen

Receptor, Notch3NOTCH3 protein, human

Autor:innen und Institutionen

  • Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Neurology, Brain Research Center, and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Stroke Research Group, Department of Clinical Neurosciences, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom.
  • Centre NeuroVasculaire Translationnel and Centre de Référence des Maladies Vasculaires Rares du Cerveau et de L'Oeil, Lariboisière Hospital and Université Paris-Cité, Paris, France.
  • Institut National de la Santé et de la Recherche Médicale, Unit 1141 NeuroDiderot, Paris, France.

Förderung

  • British Heart Foundation

Zitieren

APA

Gravesteijn, G., Rutten, J. W., Cerfontaine, M. N., Hack, R. J., Liao, Y. C., Jolly, A. A., Guey, S., Hsu, S. L., Park, J. Y., Yuan, Y., Kopczak, A., Rifino, N., Neilson, S. J., Poggesi, A., Shourav, M. M. I., Saito, S., Ishiyama, H., Domínguez Mayoral, A., Nogueira, R., …, & Lesnik Oberstein, S. A. J. (2025). Disease Severity Staging System for NOTCH3 -Associated Small Vessel Disease, Including CADASIL. JAMA Neurology, 82(1), 49. https://doi.org/10.1001/jamaneurol.2024.4487

Vancouver

Gravesteijn G, Rutten JW, Cerfontaine MN, Hack RJ, Liao YC, Jolly AA, et al. Disease Severity Staging System for NOTCH3 -Associated Small Vessel Disease, Including CADASIL. JAMA Neurology. 2025;82(1):49. doi:10.1001/jamaneurol.2024.4487

BibTeX
@article{Gravesteijn2025,
  author = {Gravesteijn, Gido and Rutten, Julie W and Cerfontaine, Minne N and Hack, Remco J and Liao, Yi-Chu and Jolly, Amy A and Guey, Stéphanie and Hsu, Shao-Lun and Park, Jae-Young and Yuan, Yun and Kopczak, Anna and Rifino, Nicola and Neilson, Sam J and Poggesi, Anna and Shourav, Md Manjurul Islam and Saito, Satoshi and Ishiyama, Hiroyuki and Domínguez Mayoral, Ana and Nogueira, Renata and Muiño, Elena and Andersen, Pia and De Stefano, Nicola and Santo, Gustavo and Sukhonpanich, Nontapat and Mele, Francesco and Park, Ashley and Lee, Jung Seok and Rodríguez-Girondo, Mar and Vonk, Sebastiaan J J and Brodtmann, Amy and Börjesson-Hanson, Anne and Pantoni, Leonardo and Fernández-Cadenas, Israel and Silva, Ana Rita and Montanaro, Vinícus V A and Kalaria, Rajesh N and Lopergolo, Diego and Ihara, Masafumi and Meschia, James F and Muir, Keith W and Bersano, Anna and Pescini, Francesca and Duering, Marco and Choi, Jay Chol and Ling, Chen and Kim, Hyunjin and Markus, Hugh S and Chabriat, Hugues and Lee, Yi-Chung and Lesnik Oberstein, Saskia A J},
  title = {Disease Severity Staging System for NOTCH3 -Associated Small Vessel Disease, Including CADASIL},
  journal = {JAMA Neurology},
  year = {2025},
  volume = {82},
  number = {1},
  pages = {49},
  doi = {10.1001/jamaneurol.2024.4487}
}
Kostenlos starten →